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Abstract
Background: Diabetes represents an increasing health burden worldwide. In 2010, the Public Health Department of
the canton of Vaud (Switzerland) launched a regional diabetes programme entitled “Programme cantonal Diabète”
(PcD), with the objectives to both decrease the incidence of diabetes and improve care for patients with diabetes.
The cohort entitled CoDiab-VD emerged from that programme. It specifically aimed at following quality of diabetes
care over time, at evaluating the coverage of the PcD within this canton and at assessing the impact of the PcD on
care of patients with diabetes.
Methods/Design: The cohort CoDiab-VD is a prospective population-based cohort study. Patients with diabetes
were recruited in two waves (autumn 2011 - summer 2012) through community pharmacies. Eligible participants
were non-institutionalised adult patients (≥18 years) with diabetes diagnosed for at least one year, residing in the
canton of Vaud and coming to a participating pharmacy with a diabetes-related prescription. Women with
gestational diabetes, people with obvious cognitive impairment or insufficient command of French were not
eligible. Self-reported data collected, included the following primary outcomes: processes-of-care indicators (annual
checks) and outcomes of care such as HbA1C, (health-related) quality of life measures (Short Form-12 Health Survey –
SF-12, Audit of Diabetes-Dependent Quality of Life 19 – ADDQoL) and Patient Assessment of Chronic Illness Care
(PACIC). Data on diabetes, health status, healthcare utilisation, health behaviour, self-management activities and
support, knowledge of, or participation to, campaigns/activities proposed by the PcD, and socio-demographics were
also obtained. For consenting participants, physicians provided few additional pieces of information about processes
and laboratory results.
Participants will be followed once a year, via a mailed self-report questionnaire. The core of the follow-up
questionnaires will be similar to the baseline one, with the addition of thematic modules adapting to the
development of the PcD. Physicians will be contacted every 2 years.
Discussion: CoDiab-VD will allow obtaining a broad picture of the care of patients with diabetes, as well as their needs
regarding their chronic condition. The data will be used to evaluate the PcD and help prioritise targeted actions.
Trial registration: This study is registered with ClinicalTrials.gov, identifier NCT01902043, July 9, 2013.
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Background
Worldwide, chronic diseases constitute a major burden
for communities in terms of morbidity, disability and mor-
tality. Their care requires collaboration between health-
care providers, teamwork, training in self-management
and the use of evidence based-medicine. However, such
care processes are complex and often suboptimal. Thus,
chronic disease management (CDM) strategies have been
developed as a means of reorganizing healthcare systems
and medical treatment for chronic diseases [1–4].
Diabetes is one of the most common chronic diseases,
with an estimated number of affected persons of more
than 550 million for 2030 [5]. In the canton of Vaud, a
Swiss state of ~720.000 residents (approximately 10 % of
the Swiss population), a recent population-based study
has shown a prevalence of diabetes of about 7 % [6]. In
2010, the Public Health Department of the canton of
Vaud initiated the development of a regional programme
entitled “Programme cantonal Diabète” (PcD), with both
the aim to decrease the prevalence of diabetes in that can-
ton and improve care for patients with diabetes [7]. The
political will and support for this innovative programme,
at the level of a whole canton, is unique in Switzerland.
Evaluation of CDM programmes is essential to assess
their implementation and determine the benefits and
effectiveness of their development [8, 9]. Randomized
controlled trials (RCT) may not be the most suitable
design for evaluating complex interventions such as the
PcD, since such interventions are very much context-
dependent [10]. In addition, there might be practical diffi-
culties to include control sites, and the resources and costs
incurred may be substantial. Moreover, when implemented
at a macro level, with no direct inclusion of patients, RCT
cannot be considered as an evaluation alternative. Scientif-
ically sound evaluation methods that remain also practical
in routine settings are needed; cohort studies may represent
such an opportunity.
To assess the impact of the implementation of the
PcD on health and care outcomes as well as to obtain a
comprehensive picture of patients with diabetes residing
in the canton of Vaud, and their care, we opted for a
prospective cohort study design. After the baseline data
collection, participants will be followed-up annually to
assess the evolution of the quality of care over time, the
coverage of the PcD within that canton and the impact
of the PcD on patients’ care.
Methods/Design
Design
The CoDiab-VD is a prospective population-based co-
hort study launched in 2011 in the canton of Vaud/
Switzerland, conducted by the Institute of Social and
Preventive Medicine (IUMSP) of the Lausanne Univer-
sity Hospital. Baseline data were collected during a two-
wave recruitment period in the autumn of 2011 and in
the summer of 2012 (Fig. 1). Patients’ follow-ups will be
set up yearly (Fig. 2).
Study population
Sampling frame
Randomly selected community-based pharmacies regis-
tered in the canton of Vaud were contacted and asked to
participate in the recruitment of patients with diabetes
[11]. During a 6 week period, participating pharmacies
had to propose the survey to 40 consecutive persons visit-
ing the pharmacy with a prescription for diabetes-related
treatment and/or equipment (oral anti-diabetic medica-
tions, insulin, glycemic strips or glucose meter). Pharma-
cists checked patients’ eligibility and briefly described the
context and aims of the study. The baseline questionnaire
package (information letter, questionnaire, prepaid reply
envelope) was given to eligible patients accepting to take
it, to complete it at home, and to return it to the investiga-
tors by regular mail. Pharmacists did not record contact
details of eligible participants because of time and organisa-
tion constraints; therefore potentially participating patients
with diabetes could not be reminded to send back the ques-
tionnaire. For the same reason, the characteristics of non-
participants could not be recorded.
Inclusion criteria
Patients were eligible if they came to a participating phar-
macy with a diabetes-related prescription, and were non-
institutionalised adults (≥18 years) reporting a diagnosis of
diabetes for at least 1 year, residing in the canton of Vaud
and able to provide written informed consent.
Exclusion criteria
Exclusion criteria at baseline were gestational diabetes, ob-
vious cognitive impairment, or insufficient level of French
to understand and complete the self-report questionnaire.
Sample size
The number of patients with diabetes to include in the
study was estimated to obtain good precision (i.e. confi-
dence interval width) around the following primary out-
comes at baseline: mean HbA1C value, mean Physical and
Mental component scores (PCS and MCS) of the Short
Form-12 Health Survey (SF-12), mean Patient Assessment
of Chronic Illness Care (PACIC) global score, and percent-
age of patients receiving recommended annual processes-
of-care. Considering the clustering of data by pharmacies
(40 pharmacies, each recruiting 15 patients, intra-class
correlation 0.05, alpha 0.05, beta 0.2), the recruitment of
600 participants was deemed appropriate. This sample
size was also large enough to detect a 0.5 % point decrease
in HbA1C between two time points. In addition, it was
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above the sample size required for such a change consid-
ering repeated measures within a same individual.
Baseline measures
Patients’ questionnaire
The baseline questionnaire was designed to encom-
pass several aspects of disease, care and life of people
living with diabetes. It targeted the following areas:
diabetes status, diabetes management and quality of
care, health-related quality of life (HRQoL) and quality
of life (QoL), health services utilisation, health status
and health habits, self-management activities and sup-
port, socio-demographics. An overview of all variables
collected is shown in Table 1, and a comprehensive
description of corresponding questionnaires and an-
swer categories is provided in the Additional file 1.
Selection of indicators
The selection of quality indicators followed a three-step
procedure. First, we searched the published and grey
literature for frequently used diabetes quality of care
indicators and population-based surveys exploring the
quality of care of patients with diabetes. Then, we identi-
fied published clinical practice guidelines on diabetes care
and considered those most recently updated and used by
a group of regional partners adapting diabetes guidelines
for Switzerland. The guidelines developed by the following
agencies were considered: National Institute for Health
and Clinical Excellence (NICE), Scottish Intercollegiate
Guidelines Network (SIGN), International Diabetes Foun-
dation (IDF), Canadian Diabetes Association (CDA),
American Diabetes Association (ADA), Haute Autorité de
Surveillance (HAS). Finally, we took into account three
criteria: clinical significance, practical relevance (feasibil-
ity), and reliability/validity of the measurement. When
several instruments existed, we considered their validity,
their length, and the existence of a French version. We
favoured instruments which presented the best balance of
those latter criteria.
Primary outcomes: processes and outcomes quality of care
indicators
We considered as primary outcomes all usually recom-
mended diabetes processes-of-care indicators, as well as
the following outcomes of care indicators: HbA1C levels,
as an intermediary outcome associated with future
development of diabetes complications [12–14], HRQoL
and QoL as measured using a generic tool (SF-12) [15]
and a diabetes-specific quality of life tool (Audit of
Diabetes-Dependent Quality of Life 19 – ADDQoL) [16],
respectively, and patient assessment of chronic care, i.e.
how care is congruent with the Chronic Care Model
(PACIC) [17, 18].
Exposure variables
In the 2012 baseline questionnaire, we also added a small
number of questions regarding knowledge and participa-
tion in the few activities proposed that year by the PcD.
These questions were only asked to patients recruited in
2012 in order to describe possible differences in terms of
exposition to, and awareness of, the PcD, because patients
were recruited over two different time periods.
Other variables of interest
The other variables of interest considered in the baseline
questionnaire are briefly described thereafter; more de-
tails are provided in Table 1 and Additional file 1.
– Diabetes characteristics and related complications;
– Medication adherence using the Morisky medication
adherence questionnaire [19];
– Healthcare utilisation within the past 12 months:
ambulatory care visits, emergency visits, hospitalisation,
home care services, domestic home support;
– Care foregone because of costs;
– Health status and health habits: anthropometric
measures (weight and height allowing the
calculation of the body mass index (BMI)), smoking
status, alcohol consumption using the AUDIT-C
questionnaire [20], levels of physical activity using
questions from the Swiss Health Survey [21],
depression screening using two validated questions
[22] and comorbidities;
– Self-management activities and support measures:
home glucose self-monitoring, HbA1C knowledge,
participation in diabetes education classes,
membership of the local diabetes association
(Association Vaudoise du Diabète – AVD),
knowledge of the “Diabetes Passport” (a small
booklet with data, information and reminders) and if
it was known, whether it was used;
– “Self-efficacy” measure, which was developed de
novo because available instruments were either not
appropriate from our point of view, or too long or
did not have a French version. We were interested
in exploring how easy/difficult it was for patients to
manage their diabetes, overall, and also specifically,
regarding the daily management of physical activity,
medication and diet;
– Level and source of information about diabetes;
– Support and satisfaction from the healthcare team
or from the members of the social network, if any;
– Overall satisfaction with current care and care
recommendation to others;
– Patients’ socio-demographic characteristics: age,
gender, nationality, place of residence, marital status,
family size, education, employment, household
income and insurance status.
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Table 1 Overview of the variables, measures and instruments used in the patient self-completed questionnaire
Section Themes Instruments, details
Primary outcomes: processes and
outcomes quality of care
indicators
Diabetes management Receipt of recommended
processes-of-care
1) Past 12 months: HbA1C check, blood pressure measurement, weight
measurement, lipid profile, diabetic foot examination, urine test for
microalbuminuria, eye examination by ophtalmologist, influenza vaccination
2) Anytime: physical activity recommendations, diet recommendations
HbA1C Last HbA1C value
Health-related quality of life
(HRQoL) and Quality of life (QoL)
Generic HRQoL SF-12 [15]
Diabetes-specific QoL ADDQoL [16]
Patient assessment of chronic
care
Congruency of care with the
Chronic Care Model (CCM)
PACIC [17, 18]
Exposure variables
Programme cantonal Diabètea Knowledge of/participation in PcD
activities/projects
Other variables of interest
Diabetes Characteristics of the disease Type of diabetes, disease duration, treatment (drugs)
Diabetes-related complications List of following complications: ischemic heart diseases, stroke, retinopathy,
chronic kidney disease (CKD) without dialysis, CKD with dialysis or kidney
transplant, neuropathy, foot ulcer, lower limb amputation, severe hypo-
or hyperglycemia
Diabetes management Medication adherence Morisky Medication Adherence Questionnaire [19]
Health services utilisation Ambulatory care visits, emergency
visits, hospitalisation
Utilisation during past 12 months
Home care services, domestic
home support
Received help during past 12 months
Foregoing care because of costs Foregoing care during past 12 months
Health status and health habits Anthropometric values Weight, height
Smoking Smoking status, duration of smoking, smoking products, average number
of cigarettes smoked per day, medical advice on smoking cessation
Alcohol consumption AUDIT-C questionnaire [20]
Physical activity levels Questions from the Swiss Health Survey [21]
Depression screening Two validated questions for the screening of depression [22]
Comorbidities List of following chronic diseases: heart disease (heart failure, valve disease,
heart muscle disease), chronic lung disease (asthma, chronic bronchitis,
emphysema), osteoporosis, osteoarthritis or arthritis; cancer or malignancy
or lymphoma (with the exception of skin cancer), gastric or duodenal ulcer,






Participation in diabetes education
courses
Membership in the local diabetes
association
Knowledge and use of the
“Diabetes Passport”b
“Self-efficacy” Level of easiness/difficulty to manage diabetes generally, and regarding
physical activity, diet, and medication
Level and source of information
about diabetes
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Pretest of the questionnaire
Before the recruitment, we pretested the questionnaire
among 12 patients with diabetes to ensure the under-
standing and acceptability of the instructions and of the
questions, as well as to measure the completion time of
the questionnaire as a whole.
Treating physicians’ questionnaire
If participants agreed to share their physicians’ contact de-
tails, the physicians were contacted and asked to complete
a questionnaire on their patients’ clinical, laboratory and
processes-of-care values, as well as a personal question-
naire including some of their characteristics and charac-
teristics of their practice (Table 2).
Patients’ information
Physicians were asked to report the type of diabetes
(type 1, type 2, other:specify), the last value and date of
the following measures: HbA1C, lipid profile, serum cre-
atinine (since the 2012 follow-up), urine microalbumi-
nurie, blood pressure, weight and height. They were also
asked to report whether the following processes-of-care
were done or not as well as the date of the examination:
foot examination, eye examination by ophthalmologist,
influenza vaccination. Finally, they had to assess satisfac-
tion with their patients’ care and management (5-point
scale: entirely satisfied to not at all satisfied), as well as
describe the barriers they were facing which prevented
them to better take care of their patients (no barrier,
insufficient time during consultation, other health prob-
lems of the patient, lack of motivation of the patient,
health insurance reimbursement or insurance problem,
language or cultural barrier, other).
Physicians’ characteristics
Physicians’ characteristics encompassed age, gender of
the physician, year of medical diploma, year of start in
private practice, and board certification type. We also
asked a few questions allowing the characterization of
their practice: location and type, activity rate, participa-
tion in quality programmes/circles.
Follow-up
Follow-up process
Participants will be followed annually by mail question-
naires (information letter, paper questionnaire and pre-
paid reply envelope). To maximise retention of participants
in the cohort, we will send a postcard reminder 2 weeks
after the first mailing to non-respondents and a complete
reminder package again 2 weeks later (questionnaire, infor-
mation letter and prepaid reply envelope). Persistent non-
respondents will be contacted by telephone; a minimum of
Table 1 Overview of the variables, measures and instruments used in the patient self-completed questionnaire (Continued)
Support and satisfaction from
healthcare team and social network
Diabetes care satisfaction and
recommandation of their care to
others
Socio-demographics Characteristics of the participants Age, gender
Socio-economic status Marital status, family size, household income, education, employment,
insurance status, place of residence, nationality
HRQoL health-related quality of life, SF-12 short form-12 Health Survey, ADDQoL audit of diabetes-dependent quality of life 19, CCM chronic care model,
PACIC patient assessment of chronic illness care
aSince the 2012 recruitment
bA small booklet with data, information and reminders




Laboratory results HbA1C, lipid profile, serum creatininea, urine microalbuminuria, blood pressure, weight,
height
Last value and date
Processes-of-care Diabetic foot examination, eye examination by ophtalmologist, influenza vaccination Done/not done and date
Global satisfaction with patient
managment
Satisfaction with patients’ care and management, barriers to better care management
Physicians’ characteristics
Personal information Age, gender, year of diploma, year of start of private practice, board certification type
Practice information Practice location, practice type, activity rate, participation in quality programmes/circles
aSince the 2012 follow-up
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three contact attempts over different days and times is
planned.
Because of time constraints and overall limited partici-
pation to research projects, treating physicians will be
contacted every 2 years only.
Follow-up questionnaires
The core of the follow-up patients’ questionnaires will be
similar to the baseline questionnaire, particularly with
regard to the questions targeting primary outcomes, health-
care utilisation, health status and health habits as well as to
the questions assessing knowledge and participation to PcD
projects. According to the needs and specific interests of
the PcD, new questions or thematic modules will be added
to the follow-up questionnaires. In 2013 for example, a
module on diabetic foot, as well as the Stanford self
efficacy questionnaire and a health literacy question
were added. In order to keep a questionnaire of a rea-
sonable length, questions representing variables other
than primary outcomes may be removed momentarily
from the follow-up questionnaire.
The physicians’ questionnaire will be similar to the base-
line one.
Data entry and analysis
Upon receipt, questionnaires are first checked for ob-
vious mistakes, and then scanned with an automated
forms processing system, TeleForm™. Exported data
are then systematically verified to detect errors. Pa-
tients’, physicians’ and pharmacies’ administrative data
are kept in separate tables. A unique ID allows to link
clinical and administrative information.
Descriptive analyses (univariate and bivariate) will be
performed first. Then, depending on the research ques-
tions, appropriate statistical analyses will be conducted.
Analyses, when appropriate, will take into account the
hierarchical structure of the data (clustering by phar-
macy and longitudinal design).
Ethical considerations
The study protocol was approved by the Cantonal Ethics
Committee of Research on Human Beings of the Canton
of Vaud (Protocol N° 151/11). This study is registered
with ClinicalTrials.gov, identifier NCT01902043. In-
formed consent was obtained from all participants, and
data will be kept anonymous.
Discussion
The implementation of CoDiab-VD followed a qualita-
tive study on the evaluation of patients’ and profes-
sionals’ needs regarding the management of diabetes in
this canton [23]. Both these first qualitative results and
CoDiab-VD baseline quantitative results were, and will
be useful for the adaptation of the PcD to the needs of
healthcare professionals caring for patients with diabetes
and other stakeholders. In addition, CoDiab-VD will be
a helpful tool i) for the pragmatic evaluation of the PcD,
and ii) for the future development and implementation
of PcD projects.
One of our study design’s strength is the recruitment
through community pharmacies [11], which allowed us
to obtain a sample probably more representative of the
population of patients with diabetes than a recruitment
through medical practices or hospitals. In fact, we hy-
pothesized that this method would limit the selection of
patients on the basis of the level of care received, this in-
formation not being available to pharmacists. However,
this hypothesis could not be confirmed by a comparison
of participants’ and non-participants’ characteristics be-
cause data on non-participants could not be collected.
Elements in favour of an acceptable representativeness
are the fact that our study participants did not differ sig-
nificantly from participants with diabetes of the CoLaus
study [6], another population-based study conducted in
the same region, regarding a few common characteristics
(age, gender, education, smoking status, BMI) (P. Marques-
Vidal, personal communication). The minor differences
probably stemmed from the fact that the population of the
latter cohort were limited to a narrower age range (35–75).
Another positive aspect of the cohort CoDiab-VD is the
fact that we collected at baseline, and plan to collect in the
future, a broad range of quality indicators that include not
only commonly considered processes-of-care but also a
variety of patient-reported outcomes. In fact, the latter en-
compass different aspects of diabetes and diabetes care that
are important to patients but nevertheless often neglected
despite the fact that they represent important measures to
take into account when wishing to capture the complexity
of the quality of diabetes care [24–26].
The cohort CoDiab-VD is, however, subject to several
limitations. First, the number of patients recruited was
below the sample size calculated (inclusion of 519 partici-
pants instead of the planed 600). However, because of a
greater number of clusters (pharmacies) than expected
and a conservative sample size calculation, the precision
around point estimates was nevertheless acceptable. This
sample size is also large enough (power > 90 %) to detect a
0.5 % point decrease in HbA1C, a PCS or MCS change of
5 points, a PACIC change of 0.3, or an absolute change of
process of care of 10 %. Second, one could criticize the
choice of self-reported data for the majority of the out-
comes, since they may be prone to recall bias – an inher-
ent limitation of such data collection, or be over- or
underestimated. Specific analyses, on a fraction of the
cohort data, demonstrated a good agreement between
patient- and physician-reported outcomes for simple
processes-of-care, such as measurement of blood pressure,
HbA1C, weight and lipid profile [27]. Physician-reported
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outcomes were asked for in a second phase. Since their
collection was dependent on the physicians’ willingness to
participate, these variables were only available for a frac-
tion of the sample, about 50 % at both recruitments and
first follow-up. We will nevertheless favour the collection
of some physician-reported measures (i.e. blood pressure,
HbA1C value) in the future because they are more accur-
ate. Third, between the 2011 baseline recruitment and
their first follow-up in 2012, 58 patients refused to con-
tinue to participate in the cohort, what could be explained
by the lack of information of the 2011 initial group of pa-
tients about the annual follow-ups to come. Globally how-
ever, when considering patients both recruited in 2011
and in 2012, this amounted to only a tenth of the total
baseline sample size. In addition, the comparison of char-
acteristics of participants to the baseline and of partici-
pants to the 2013 follow-up did not highlight major
differences.
CoDiab-VD will allow drawing a broad picture of pa-
tients with diabetes and their care over time. It will also
contribute to the evaluation of the PcD and to support
decisions about which targeted actions to implement.
Additional file
Additional file 1: Detailed description of the patients’
questionnaire. A comprehensive description of the patients’
questionnaire regarding the different variables and validated instruments
included, as well as their response options or scoring. (DOCX 40 kb)
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